The question is the sustainability of that increase, and if we need new lines of drugs that are being protected under patents—and they're not being produced all over the place, as seems to be implied at the moment, for distribution—then the problem is not going to be improved. Of course, while we have the first line, they can use them.
The issue about other countries having this legislation in place is that many of them have not tried to use their August 30 legislation. One of the reasons was that they were looking to Canada to see how Canada would behave, how Canada would be able to make it work, and many countries are still waiting to see that.
There will be new discussions at the WTO about the August 30 decision and why it's not working, and how to make it a functional thing. I believe we need to have more solutions on how to get the correct medicines to people. The second line of the AIDS crisis is showing that.